ANGANY CEO Dr. Louis-Philippe Vézina is very pleased to announce the collaboration of world-renowned Pr. Durham and Pr. Shamji, authorities in the field of allergy, to the activities of its…
Read More
News
Mr. St-Gelais is a director and business manager with an academic background in medicine and finance. A CFA charterholder, Mr. St-Gelais carries over twenty years of management experience mainly in…
ANGANY CEO Louis-Philippe Vézina is pleased to announce the nomination of Pr. Ronald van Ree PhD, as chairperson of ANGANY’s Scientific Advisory Board. Pr. Van Ree heads the Laboratory for…
Lévis, QC. – Built by Mecart Inc. of St-Augustin-de-Desmaures, QC during the challenging context of a pandemic, this production and analytic suite greatly adds to ANGANY’s operational capabilities and will…
Dr. Carrier brings over 20 years of management experience in the pharmaceutical industry with a history of success in developing, submitting and approving multiple drug applications in Canada, United States…
ANGANY has contracted the installation of a manufacturing pilot unit in clean rooms. This will provide a capacity to manufacture clinical batches in GMP conditions for Phase I and Phase…
A Franco-Canadian start-up is tackling allergic dermatitis delivery with immunotherapy treatments produced by plants. Animalpharm
Reims, France. – In her invited presentation Dr. Gomord reviewed new avenues in allergy immunotherapy. http://ciaballergie.org/
Orlando, FL. -High level executive exchanges were held with select veterinary pharmaceutical companies from around the world, particularly with regards to ANGANY’s canine atopic dermatitis (CAD) products under development. https://navc.com/vmx/
Canadian pharma start-up enlists LEVOYA to move further into animal health. Animalpharm
